They now run a lab at the Broad Institute in Boston. By 2024 they had created an editor that, in mice, turns off the prion gene in the brain, preventing the disease from taking hold. Next up is making ...
Centurion University hosted the National Conference on “Frontiers in Genetics and Genomics”. The event brought together ...
Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine’s presentations, please visit the ...
Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
India aims to double horticulture output to 700 million tonnes by 2047, focusing on high-yielding, climate-resilient ...
CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...
The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...
Scientists are exploring gene editing as a way to correct trisomy at the cellular level. Using CRISPR-Cas9, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results